UNIVEST FINANCIAL Corp Purchases 110 Shares of Thermo Fisher Scientific Inc. (NYSE:TMO)

UNIVEST FINANCIAL Corp grew its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.0% in the second quarter, HoldingsChannel reports. The fund owned 11,225 shares of the medical research company’s stock after buying an additional 110 shares during the period. Thermo Fisher Scientific accounts for 1.7% of UNIVEST FINANCIAL Corp’s portfolio, making the stock its 15th largest position. UNIVEST FINANCIAL Corp’s holdings in Thermo Fisher Scientific were worth $6,207,000 at the end of the most recent quarter.

A number of other institutional investors have also recently bought and sold shares of TMO. Private Wealth Management Group LLC acquired a new position in Thermo Fisher Scientific in the 4th quarter valued at $110,000. Brookstone Capital Management increased its holdings in Thermo Fisher Scientific by 252.4% in the 1st quarter. Brookstone Capital Management now owns 4,387 shares of the medical research company’s stock valued at $2,550,000 after buying an additional 3,142 shares during the period. Artisan Partners Limited Partnership bought a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $40,335,000. Leo Wealth LLC acquired a new stake in shares of Thermo Fisher Scientific during the 4th quarter worth approximately $1,117,000. Finally, Jump Financial LLC acquired a new position in Thermo Fisher Scientific during the fourth quarter valued at approximately $1,399,000. Institutional investors own 89.23% of the company’s stock.

Analyst Upgrades and Downgrades

TMO has been the subject of a number of research analyst reports. Raymond James upped their price objective on shares of Thermo Fisher Scientific from $650.00 to $660.00 and gave the stock an “outperform” rating in a research report on Thursday, July 25th. Royal Bank of Canada increased their price target on Thermo Fisher Scientific from $660.00 to $664.00 and gave the company an “outperform” rating in a research note on Thursday, July 25th. Stifel Nicolaus upped their target price on Thermo Fisher Scientific from $600.00 to $615.00 and gave the stock a “buy” rating in a report on Thursday, July 25th. Robert W. Baird lifted their target price on Thermo Fisher Scientific from $620.00 to $632.00 and gave the stock an “outperform” rating in a report on Thursday, July 25th. Finally, TD Cowen raised their price objective on shares of Thermo Fisher Scientific from $648.00 to $658.00 and gave the stock a “buy” rating in a research report on Thursday, July 25th. Four equities research analysts have rated the stock with a hold rating and fifteen have issued a buy rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and an average price target of $630.41.

Thermo Fisher Scientific Trading Up 0.7 %

NYSE TMO opened at $611.35 on Friday. The company has a current ratio of 1.72, a quick ratio of 1.37 and a debt-to-equity ratio of 0.64. The firm has a market capitalization of $233.54 billion, a P/E ratio of 39.21, a PEG ratio of 2.85 and a beta of 0.78. The business has a fifty day simple moving average of $584.07 and a 200 day simple moving average of $577.99. Thermo Fisher Scientific Inc. has a 12 month low of $415.60 and a 12 month high of $622.30.

Thermo Fisher Scientific (NYSE:TMO) last posted its earnings results on Wednesday, July 24th. The medical research company reported $5.37 EPS for the quarter, topping the consensus estimate of $5.13 by $0.24. The firm had revenue of $10.54 billion for the quarter, compared to analysts’ expectations of $10.50 billion. Thermo Fisher Scientific had a net margin of 14.69% and a return on equity of 18.22%. The company’s quarterly revenue was down 1.4% compared to the same quarter last year. During the same quarter last year, the firm earned $5.15 EPS. On average, analysts predict that Thermo Fisher Scientific Inc. will post 21.72 EPS for the current fiscal year.

Thermo Fisher Scientific Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, October 15th. Investors of record on Friday, September 13th will be issued a $0.39 dividend. This represents a $1.56 dividend on an annualized basis and a dividend yield of 0.26%. The ex-dividend date is Friday, September 13th. Thermo Fisher Scientific’s dividend payout ratio (DPR) is currently 10.01%.

Insider Buying and Selling

In other Thermo Fisher Scientific news, CEO Marc N. Casper sold 10,000 shares of the business’s stock in a transaction dated Wednesday, July 31st. The shares were sold at an average price of $617.21, for a total value of $6,172,100.00. Following the transaction, the chief executive officer now directly owns 123,816 shares in the company, valued at $76,420,473.36. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. In related news, CEO Marc N. Casper sold 10,000 shares of the company’s stock in a transaction that occurred on Wednesday, July 31st. The stock was sold at an average price of $617.21, for a total value of $6,172,100.00. Following the transaction, the chief executive officer now owns 123,816 shares in the company, valued at $76,420,473.36. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website. Also, CEO Marc N. Casper sold 6,300 shares of the firm’s stock in a transaction on Monday, July 29th. The stock was sold at an average price of $602.09, for a total value of $3,793,167.00. Following the completion of the sale, the chief executive officer now directly owns 123,816 shares of the company’s stock, valued at $74,548,375.44. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 23,084 shares of company stock worth $14,094,292. Insiders own 0.34% of the company’s stock.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.